CRISPRi screens reveal a DNA methylation-mediated 3D genome dependent causal mechanism in prostate cancer

Musaddeque Ahmed1, Fraser Soares1, Ji-Han Xia2

  • 1Princess Margaret Cancer Center/University Health Network, Toronto, ON, Canada.

Nature Communications
|March 20, 2021
PubMed

Insights

Prostate cancer risk SNPs in regulatory elements impact cell growth. DNA methylation and CTCF binding at a specific site control MYC expression, influencing tumor development.

Area of Science:

  • Genomics
  • Epigenetics
  • Cancer Biology

Background:

  • Prostate cancer (PCa) risk-associated single nucleotide polymorphisms (SNPs) are found in cis-regulatory elements (rCREs).
  • The functional roles and clinical significance of these rCREs are not fully understood.

Purpose of the Study:

  • To investigate the functional impact of rCREs harboring PCa risk SNPs.
  • To elucidate the mechanisms by which these elements influence gene expression and tumorigenesis.

Main Methods:

  • CRISPR interference (CRISPRi) screens were conducted on 260 rCREs in PCa cell lines.
  • Histone modification (H3K27ac) occupancy and DNA methylation levels were analyzed.
  • Expression quantitative trait locus (eQTL) analysis was performed on prostate specimens.

Main Results:

  • rCREs with high-risk SNPs are crucial for PCa cell proliferation, with H3K27ac occupancy indicating essentiality.
  • Cell-line-specific essential rCREs in the 8q24.21 region, including rs11986220, regulate MYC and PVT1 expression.
  • DNA methylation-controlled CTCF binding at a specific site mediates the cell-line-specific regulation of MYC by the rs11986220-containing rCRE.
  • CTCT binding variability in prostate specimens correlates with MYC eQTLs in individuals with low CTCF binding.

Conclusions:

  • A causal mechanism involving risk SNPs and DNA methylation-driven 3D genome architecture drives PCa.
  • Integrating genetic and epigenetic data is crucial for assessing risks associated with genetic predispositions in prostate cancer.